MMP-cleavable linker platform for tumour-responsive homo- and heterobivalent antibody–drug conjugates
Open Access
- 3 December 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (5) , 2722-2731
Abstract
Herein we report the development of a novel linker platform for tumour-responsive antibody–drug conjugates.Keywords
Funding Information
- Engineering and Physical Sciences Research Council
- Biotechnology and Biological Sciences Research Council
- UK Research and Innovation
- Cystic Fibrosis Trust
- Cancer Research UK
This publication has 53 references indexed in Scilit:
- EGFR-directed antibodies promote HER2 ADC internalization and efficacyCell Reports Medicine, 2024
- Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agentsNeoplasia, 2024
- Microenvironment-responsive anti-PD-L1 × CD3 bispecific T-cell engager for solid tumor immunotherapyJournal of Controlled Release, 2023
- A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacyJournal of Biological Chemistry, 2021
- Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancerCritical Reviews in Oncology/Hematology, 2019
- Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug deliveryDrug Discovery Today: Technologies, 2018
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretionCancer Letters, 2018
- PSMA-targeted bispecific Fab conjugates that engage T cellsBioorganic & Medicinal Chemistry Letters, 2017
- Type I receptor tyrosine kinases are associated with hormone escape in prostate cancerThe Journal of Pathology, 2005
- Bioconjugation of Peptides by Palladium-Catalyzed C−C Cross-Coupling in WaterAngewandte Chemie International Edition, 1998